SALT LAKE CITY, Feb. 1, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will hold a conference call on Wednesday, Feb 9, 2011 at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results for its fiscal second quarter 2011 ended December 31, 2010.
The conference call will be hosted by Adrian Hobden, Ph.D., President and Chief Executive Officer and Robert Lollini, Chief Financial Officer and Treasurer.
To participate, please dial 877-312-5447 (USA) or 253-237-1129 (International); Conference ID: 41570338. To access the live web cast please visit the Investor Relations section on the corporate web site at www.myrexis.com.A replay of the conference call will be available beginning February 9, 2011 at 7:30 p.m. ET (4:30 p.m. PT) and ending on March 9, 2011 by dialing 800-642-1687 (USA) or 706-645-9291 (International), Conference ID: 41570338. A replay of the webcast will also be available on the corporate website for one month, through March 9, 2011. About Myrexis, Inc. Myrexis, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer. The Company has leveraged a unique understanding of the genetic causes of human disease to generate a robust pipeline of clinical and pre-clinical product candidates. These include compounds with distinct mechanisms of action and novel chemical structures that have first-in-class and/or best-in-class therapeutic potential. Myrexis is led by an experienced management team with expertise in human genetics, protein-protein interaction technology, chemical proteomics, drug discovery and clinical and commercial development. The Company's oncology pipeline is led by Azixa (verubulin, MPC-6827), a novel small molecule microtubule destabilizing agent in Phase 2 clinical development for the treatment of brain cancers. Additional novel, potent, small molecule oncology compounds include MPC-3100, a fully-synthetic inhibitor of Hsp90 in Phase 1 clinical development; and MPC-9528, a Cancer Metabolism Inhibitor (CMI) in IND-enabling studies. Myrexis is also evaluating MPI-0485520, an orally bioavailable, potent and selective small molecule inhibitor of type I interferon production that is being developed for cancer and chronic inflammation. For more information, please visit www.myrexis.com . The Myrexis, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6327 Azixa, Myrexis and the Myrexis logo are trademarks or registered trademarks of Myrexis, Inc. in the United States and foreign countries.